TheScreener - Vital Therapies Inc (VTL) An unfavourable environment weighs on VITAL THERAPIES INCO., which sees a downgrade to Negative

Report

TheScreener

EUR 12.95 For Business Accounts Only

An unfavourable environment weighs on VITAL THERAPIES INCO., which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of VITAL THERAPIES INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date October 12, 2018, the closing price was USD 0.33 and its target price was estimated at USD -1.58.

13/10/2018 5 EN

Underlying

Vital Therapies Inc

Vital Therapies clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapies capable of transforming the management of life-threatening conditions. The company's product candidate, the ELAD? System, is an investigational, extracorporeal human hepatic cell-based liver treatment designed to supplement hepatic function in order to improve survival rates among patients with acute forms of liver failure. In addition, the company is also exploring the use of proteins produced by its VTL C3A cells to resuscitate donated livers prior to transplantation into patients as there is a need to increase the number and quality of livers available for transplant.

See profile

US92847R1041 United States

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

GlobeNewsWire

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019 SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April. In connection with the closing of the transaction, Vital Therapies will change its name to Immun...

April 10, 2019 April 10, 2019 1 EN

GlobeNewsWire

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today. Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We...

April 4, 2019 April 4, 2019 1 EN

GlobeNewsWire

Vital Therapies Reminds Stockholders to Vote ForÂ the Proposed Business Combination With Immunic AG

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG Of the Votes Received to Date, More than 98% are Voting in Favor of the Business CombinationMore Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go ForwardEvery Vote is Important to Avoid Delay in Completion of the Business Combination SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholder...

March 27, 2019 March 27, 2019 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

An unfavourable environment weighs on VITAL THERAPIES INCO., which sees a downgrade to Negative

Empowering Investors

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019

Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG

Vital Therapies Reminds Stockholders to Vote ForÂ the Proposed Business Combination With Immunic AG

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe